Article type
Year
Abstract
Background:
Clinical practice guidelines are statements that include recommendations for the optimization of patient care. To support the health care decisions, policy and decision makers need reliable information on the cost-effectiveness of health care interventions. Economic evidence is becoming influential in HTA world-wide, and important components of the economic evidence used in the development of CPGs, so that the use of HTA as evidence in the guidelines is crucial.
Objectives:
The aim of the study is to investigate how HTA have been cited in clinical practice guidelines.
Methods:
We conducted a cited reference search with the cited titles including 'health technology assessment' in the Web of Science database to identify articles using HTA. We screened all records identified in the search. We included guidelines published until 31th Oct. 2019 and excluded non-English. Two researchers independently screened the records and extracted data; disagreements were resolved through discussion.
Results:
We searched four hundred thirty-two papers and identified a total of thirty-two eligible guidelines. Most guidelines were developed in the USA (n=8, 25%) and Canada (n=5, 16%); twenty-five (78%) guidelines were original versions. Sixteen (50%) guidelines had multiple topics, fifty (47%) guidelines were for only treatment, and fifty (47%) for management. twenty-two (69%) guideline cited twenty-nine HTA reports, seventy-seven (77%) cited one HTA report, the first cited HTA report was published in 1999, one (5%) cited five HTA reports; and the highest number cited were published in 2019, which is NICE guideline, one (5%) cited only HTA systematic review.
Conclusions:
Although a majority of guidelines use HTA to support recommendations, the average number is very small. Guideline developers should use more systematic review of HTA in Evidence Summary
Patient or healthcare consumer involvement:
None
Clinical practice guidelines are statements that include recommendations for the optimization of patient care. To support the health care decisions, policy and decision makers need reliable information on the cost-effectiveness of health care interventions. Economic evidence is becoming influential in HTA world-wide, and important components of the economic evidence used in the development of CPGs, so that the use of HTA as evidence in the guidelines is crucial.
Objectives:
The aim of the study is to investigate how HTA have been cited in clinical practice guidelines.
Methods:
We conducted a cited reference search with the cited titles including 'health technology assessment' in the Web of Science database to identify articles using HTA. We screened all records identified in the search. We included guidelines published until 31th Oct. 2019 and excluded non-English. Two researchers independently screened the records and extracted data; disagreements were resolved through discussion.
Results:
We searched four hundred thirty-two papers and identified a total of thirty-two eligible guidelines. Most guidelines were developed in the USA (n=8, 25%) and Canada (n=5, 16%); twenty-five (78%) guidelines were original versions. Sixteen (50%) guidelines had multiple topics, fifty (47%) guidelines were for only treatment, and fifty (47%) for management. twenty-two (69%) guideline cited twenty-nine HTA reports, seventy-seven (77%) cited one HTA report, the first cited HTA report was published in 1999, one (5%) cited five HTA reports; and the highest number cited were published in 2019, which is NICE guideline, one (5%) cited only HTA systematic review.
Conclusions:
Although a majority of guidelines use HTA to support recommendations, the average number is very small. Guideline developers should use more systematic review of HTA in Evidence Summary
Patient or healthcare consumer involvement:
None